TREMFYA is now U.S. FDA-approved for ulcerative colitis and under review for Crohn's disease

TREMFYA is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naïve and biologic-refractory

Ninety percent more biologic-naïve patients and three times more biologic-refractory patients with ulcerative colitis achieved endoscopic remission with TREMFYA

VIENNA, Austria, Oct. 10, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced TREMFYA (guselkumab) data in both Crohn's disease (CD) and ulcerative colitis (UC) showing high rates of endoscopic remission in both biologic-naïve and biologic-refractory patients (including UC patients refractory to JAK inhibitors), indicating a normal appearance of intestinal mucosa.1,2 These subgroup analyses are from pooled data from the Phase 3 GALAXI 2 & 3 studies of TREMFYA in adults with moderately to severely active CD and the Phase 3 QUASAR maintenance study of TREMFYA in adults with moderately to severely active UC. These findings are among 19 Johnson & Johnson abstracts being presented at the United European Gastroenterology (UEG) Week 2024. TREMFYA is under review for the treatment of adults with moderately to severely active UC and CD by the European Medicines Agency (EMA).